tooluniverse-stem-cell-organoid

Stem Cell & Organoid Research

Pipeline for investigating stem cell biology, iPSC characterization, organoid models, and cell differentiation using ToolUniverse tools.

Reasoning Strategy

Stem cell differentiation follows developmental biology — to make any target cell type from iPSCs, the protocol must mimic the embryonic signaling pathway that generates that cell type in vivo. For neural induction: inhibit BMP and TGF-beta (dual SMAD inhibition). For cardiomyocytes: activate WNT then inhibit WNT. For pancreatic beta cells: activate Activin/Nodal → FGF → Notch inhibition → BMP in sequence. The order and timing of growth factors matters critically — adding BMP4 during neural induction will redirect cells toward mesoderm. Mouse and human stem cells differ in their signaling requirements (LIF/STAT3 for mouse naive pluripotency; FGF/ERK for human primed pluripotency), so protocols are not interchangeable. Organoids recapitulate some but not all organ features — always assess maturation state (fetal vs. adult gene expression) before drawing disease-relevance conclusions.

LOOK UP DON'T GUESS: Do not assume which markers define a target cell type or which signaling pathway drives differentiation — query CellMarker_search_by_cell_type for markers and kegg_search_pathway for the relevant pathway. Do not assume organoid fidelity; look up published CellxGene or HCA atlas data for comparison.

Key principles:

1. Marker-based identity — stem cell identity is defined by marker expression profiles (OCT4, SOX2, NANOG for pluripotency)
2. Differentiation is a trajectory — not a binary state; analyze intermediate progenitor stages
3. Organoid ≠ organ — organoids recapitulate some but not all organ features; always note limitations
4. Species matters — mouse and human stem cells differ in signaling requirements
5. Evidence grading — T1: validated in clinical iPSC study, T2: functional assay (teratoma, engraftment), T3: marker expression only, T4: computational prediction

---

Core Tools

Tool	Use For
CELLxGENE_get_census_versions	Discover CELLxGENE Census release versions; then use CELLxGENE_get_cell_metadata / CELLxGENE_get_expression_data for specific cells / genes. Requires cellxgene-census package (pip install cellxgene-census). May not be installed by default.
CellMarker_search_by_cell_type	Cell type marker genes. Requires operation="search_by_cell_type", cell_name= (NOT cell_type=)
CellMarker_search_by_gene	Which cell types express a gene. Requires operation="search_by_gene", gene_symbol=
hca_search_projects	Human Cell Atlas organoid/development projects
GEO_search_rnaseq_datasets	Find stem cell RNA-seq datasets
kegg_search_pathway	Differentiation signaling pathways (WNT, Notch, Hedgehog)
ReactomeAnalysis_pathway_enrichment	Pathway analysis of stem cell gene sets
STRING_get_network	Pluripotency/differentiation gene networks
OpenTargets_get_associated_targets_by_disease_efoId	Disease genes for organoid disease modeling
PubMed_search_articles	Stem cell and organoid literature
search_clinical_trials	iPSC-based clinical trials

---

Workflow

Phase 0: Define the Question
  Pluripotency? Differentiation? Disease modeling? Drug screening?
    |
Phase 1: Cell Identity & Markers
  CellMarker → pluripotency/lineage markers → verify identity
    |
Phase 2: Differentiation Pathways
  KEGG/Reactome → WNT, Notch, BMP, FGF signaling
    |
Phase 3: Atlas & Dataset Discovery
  CellxGene/HCA → reference datasets for target cell type
    |
Phase 4: Disease Modeling (if applicable)
  OpenTargets → disease genes → organoid recapitulation assessment
    |
Phase 5: Report
  Evidence-graded findings with clinical translation potential

Phase 1: Cell Identity & Markers

Pluripotency markers (must be co-expressed): OCT4 (POU5F1), SOX2, NANOG (essential); SSEA-4, TRA-1-60 (human surface markers). KLF4 and MYC are Yamanaka factors but also expressed in somatic cells — do not rely on them alone. Use CellMarker_search_by_cell_type to retrieve the full validated marker set for any target cell type.

Lineage markers: Ectoderm → PAX6/SOX1 (early), MAP2/TUBB3 (neurons); Mesoderm → TBXT/MIXL1 (early), CD34 (blood); Endoderm → SOX17/FOXA2 (early), PDX1/NKX6.1 (pancreas). Retrieve current marker lists from CellMarker rather than relying on memory.

Phase 2: Differentiation Pathways

Key signaling pathways for directed differentiation:

Pathway	KEGG ID	Role in Stem Cells	Common Modulators
WNT signaling	hsa04310	Pluripotency maintenance (canonical) vs differentiation (non-canonical)	CHIR99021 (activator), IWP-2 (inhibitor)
Notch signaling	hsa04330	Lateral inhibition, fate decisions	DAPT (gamma-secretase inhibitor)
BMP/TGF-beta	hsa04350	Mesoderm/trophectoderm induction	BMP4 (activator), Noggin (inhibitor)
FGF signaling	hsa04010	Self-renewal, neural induction	bFGF (activator), SU5402 (inhibitor)
Hedgehog	hsa04340	Patterning, organoid maturation	SAG (activator), cyclopamine (inhibitor)
Hippo/YAP	hsa04390	Mechanotransduction, organoid size	Verteporfin (YAP inhibitor)

Phase 3: Atlas & Dataset Discovery

# Find stem cell single-cell datasets
CELLxGENE_get_census_versions()  # discover available Census releases, then use CELLxGENE_get_cell_metadata / CELLxGENE_get_expression_data
hca_search_projects(query="organoid")
GEO_search_rnaseq_datasets(query="iPSC differentiation neural", organism="Homo sapiens")

Phase 4: Organoid Model Assessment

Organoid fidelity scoring — how well does the organoid recapitulate the organ?

Feature	High Fidelity (3)	Moderate (2)	Low (1)
Cell type diversity	All major cell types present	Most cell types, missing rare ones	Only 1-2 cell types
Architecture	Self-organized, correct spatial arrangement	Partial organization	Disorganized aggregate
Function	Measurable organ function (secretion, contraction, electrophysiology)	Some functional markers	Marker expression only
Maturation	Adult-like gene expression profile	Fetal-like	ESC-like (failed differentiation)
Disease relevance	Recapitulates patient phenotype	Some disease features	No disease phenotype

---

Evidence Grading

Grade	Criteria	Example
T1	Clinical iPSC study or approved therapy	iPSC-derived RPE for macular degeneration (Mandai 2017)
T2	Functional validation (teratoma, engraftment, drug response)	Organoid drug screening with patient-specific response
T3	Marker expression + morphology	iPSC colony expressing OCT4/SOX2/NANOG
T4	Computational prediction or single-marker evidence	Predicted pluripotent by gene expression classifier

Synthesis Questions

1. Is the cell identity verified? (co-expression of 3+ pluripotency markers, or lineage-appropriate markers)
2. Is the differentiation protocol reproducible? (published, peer-reviewed, with quantified efficiency)
3. Does the organoid model the disease? (patient-derived iPSC shows disease phenotype in organoid)
4. What are the translational barriers? (scalability, maturation, immune compatibility, tumorigenicity)
5. What's the best reference dataset? (CellxGene atlas for comparison)

---

Limitations

• No organoid protocol database — protocols are scattered across publications; use PubMed search
• Maturation gap — most organoids resemble fetal, not adult tissue; always note maturation state
• Batch variability — iPSC-derived cells vary between passages and donor lines
• No direct culture tools — this skill analyzes published data and designs experiments; it does not control bioreactors
• Species differences — mouse ESCs require LIF; human ESCs require bFGF. Don't mix protocols